The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Fox News senior medical analyst Dr. Marc Siegel weighs in on President Donald Trump's pharmaceutical executive order aiming to cut drug prices for Americans. Feeling snacky? Everyone knows you can ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.